Investment Pitches

Pitch Summary:
American Superconductor Corp. designs and manufactures power electronics and control systems for electricity transmission, distribution, and infrastructure. End markets include electric grids, wind power, industrial and naval. Our strategy's screening process identified the company when its largest customer at the time, a Chinese wind turbine manufacturer, stole its IP resulting in a 75% revenue decline. Our investment thesis was that the rebuilt company, following an IP litigation victory, was in a good position to resume earnings growth with significant upside potential driven by demand for electric grid upgrades, growth of wind power, and naval program wins. The stock performed well during the period on continued strong earnings and revenue growth that beat expectations. We trimmed our holdings during the quarter following strong performance as part of our normal risk management process, but maintain a position given the company's strong performance and potential upside.

BSD Analysis:
The manager's thesis on American Superconductor represents a classic turnaround opportunity following a severe business disruption caused by intellectual property theft. The investment was initiated when the company was rebuilding after a Chinese customer's IP theft caused a 75% revenue decline, creating an attractive entry point for a fundamentally sound business. The thesis centered on AMSC's recovery potential following successful IP litigation and the company's positioning in high-growth end markets including electric grid modernization, renewable energy, and naval applications. Strong recent earnings and revenue growth that exceeded expectations validate the turnaround story and demonstrate the company's successful business reconstruction. The decision to trim holdings reflects disciplined risk management following strong performance, while maintaining exposure acknowledges continued upside potential. AMSC benefits from secular tailwinds in grid infrastructure investment, renewable energy adoption, and defense spending, providing multiple growth drivers. The company's specialized power electronics and control systems technology positions it well to capitalize on the ongoing energy transition and grid modernization requirements.

Pitch Summary:
Tenet Healthcare Corp. is a top-ten U.S. operator of hospitals, outpatient surgery centers, and healthcare business process services. We initiated our position in late 2022 on the belief that the market's short-term focus on COVID-caused staffing and admissions challenges overshadowed the value of Tenet's long-term strategy of growing outpatient surgery centers. Tenet accelerated the transition of its business this year toward high-margin and higher return-on-capital surgery centers by divesting hospitals. The market rewarded the shift with a 26% return in the period. Tenet remains a top five holding with growth driven by surgery centers and a continued attractive valuation.

BSD Analysis:
The manager's thesis on Tenet Healthcare focuses on a strategic transformation from traditional hospital operations to higher-margin outpatient surgery centers. The investment was initiated when COVID-related challenges masked the underlying value of Tenet's long-term strategic pivot. The manager recognized that market concerns about staffing and admissions were temporary headwinds that obscured the company's structural shift toward more profitable business lines. Tenet's acceleration of hospital divestitures and surgery center expansion has validated this thesis, with the market recognizing the improved business mix through strong stock performance. The 26% quarterly return reflects investor appreciation for the higher-margin, higher-return-on-capital profile of surgery centers compared to traditional hospital operations. As a top five holding, Tenet represents a core conviction position benefiting from secular trends toward outpatient care and the company's successful execution of its transformation strategy. The continued attractive valuation suggests further upside potential as the surgery center growth strategy progresses and generates improved financial metrics.

Pitch Summary:
Perrigo Company plc. is the leading in-store brand for consumer wellness and self-care products. The company endured several years of declining earnings due to what we believe was poor capital allocation by its previous management team, which chased growth through acquisitions outside of Perrigo's core business. Our investment in Perrigo was inspired by a new management team that committed to pursuing realistic, steady growth rates within the core business, and delivering improved profitability and returns on capital. Despite reporting inline earnings results and maintaining annual guidance during the quarter, Perrigo stock has been weak. Market data and drug store company results have indicated a lower-than-average cough, cold, and allergy season that might be impacting short-term results. We increased our position as we believe the risk vs. reward is in our favor. In our view, Perrigo is well positioned for significant earnings growth in 2025 and beyond while trading at a current valuation of 10x current year earnings per share.

BSD Analysis:
The manager's thesis on Perrigo centers on a classic turnaround story driven by new management's strategic refocus on core operations. The previous management's value-destructive acquisition strategy outside the core consumer wellness business created the opportunity for improvement under new leadership. The investment rationale emphasizes management's commitment to disciplined capital allocation, realistic growth targets, and improved returns on invested capital. Despite recent stock weakness attributed to seasonal headwinds in the cough, cold, and allergy category, the manager views this as a temporary factor rather than a structural issue. The decision to increase the position reflects confidence in the risk-reward profile at current levels. Trading at 10x current year earnings provides an attractive entry point for anticipated earnings growth acceleration in 2025 and beyond. The consumer wellness and self-care market offers stable demand characteristics, and Perrigo's leading position in store brands provides defensive qualities with upside potential as operational improvements take hold.

Pitch Summary:
Cerence, Inc. develops human-automotive interface software that provides drivers and passengers with applications ranging from infotainment to safety and, eventually, autonomous driving. We became shareholders when the company was spun off from a previous holding and the market assigned little value to the new company. The stock performed strongly for us initially and we were able to harvest significant profits. We maintained a position despite weak results over the past two years due to our belief that Cerence's large market share, with software in over 50% of cars globally, should lead to significant growth opportunities. During the quarter the stock pulled back on missed earnings and reduced full-year and long-term forecasts. This continued poor fundamental performance convinced us that we might be wrong about the market opportunity, and we sold our entire position.

BSD Analysis:
The manager's original thesis on Cerence was built around the company's dominant market position in automotive interface software, with presence in over 50% of cars globally providing a strong foundation for growth. The investment began as a spinoff opportunity where the market initially undervalued the standalone entity. Despite early success and profit-taking, the manager maintained exposure based on the belief that Cerence's market leadership would translate into significant growth as automotive technology advanced. However, persistent weak fundamentals over two years, culminating in missed earnings and reduced guidance, forced a reassessment of the investment thesis. The complete exit reflects the manager's conclusion that the anticipated market opportunity may not materialize as expected, possibly due to competitive pressures or slower adoption of advanced automotive technologies. The automotive software market faces challenges from tech giants and changing OEM strategies, which may have undermined Cerence's competitive moat despite its historical market share.

Pitch Summary:
National Vision Holdings, Inc. is the second-largest optical retailer in the U.S. and a leader in the low-cost space with its America's Best and Eyeglass World brands. Our interest in the company began after earnings declined due to (1) tough pandemic comps (stimulus checks boosted sales and pulled ahead glasses demand) and (2) eye exam capacity constraints resulting from a challenging optometrist hiring environment. We invested based on our belief that by implementing technology to improve optometrist utilization, the company could return to its historical pattern of steady revenue and earnings growth. National Vision beat earnings during the quarter but missed sales expectations, calling into question its ability to meet expectations for annual results. We reduced our position due to evidence that the company continues to underperform the overall industry, raising suspicion that there could be problems with the business that we did not foresee. We maintain a small position as we believe it is reasonable that their improvement efforts could pay off later this year.

BSD Analysis:
The manager's thesis on National Vision was based on a turnaround story following pandemic-related headwinds and optometrist staffing challenges. The investment rationale centered on technology implementation to improve optometrist utilization and restore historical growth patterns. However, the company's recent performance has undermined this thesis, with sales misses despite earnings beats indicating potential structural issues. The manager's decision to reduce the position reflects growing concerns about the company's ability to regain market share and execute its improvement strategy. While maintaining a small position suggests some residual optimism, the overall stance has shifted bearish due to continued underperformance relative to industry peers. The optical retail sector faces ongoing challenges from online competition and changing consumer behavior post-pandemic. National Vision's struggles to meet sales expectations despite cost management efforts suggest deeper operational or competitive issues that may require more time to resolve than initially anticipated.

Pitch Summary:
Remitly Global, Inc. is a digitally native money transfer company that is taking share in the remittance market from established competitors such as Western Union and MoneyGram. The stock underperformed during the period on slightly lower than expected net new customers, though the company beat top-line EBIDTA estimates and reaffirmed positive guidance for the year. We are not concerned about the softness in net new customers in the historically slow post-holiday period and continue to have confidence in the business model and management team. As such, we maintained our position during the quarter.

BSD Analysis:
The manager maintains strong conviction in Remitly's market share capture story within the large remittance market, viewing temporary customer acquisition softness as seasonal rather than structural. The investment thesis is built on Remitly's digital-native advantage over legacy competitors like Western Union and MoneyGram, enabling superior customer experience and cost structure. Despite missing net new customer expectations, the company's ability to beat EBITDA estimates and reaffirm positive guidance demonstrates operational efficiency and margin expansion capabilities. The manager's confidence in both the business model and management team suggests strong execution against the market opportunity. The remittance market represents a large, stable addressable market with significant digitization potential, positioning Remitly for sustained growth. The post-holiday seasonal weakness appears temporary given historical patterns, supporting the manager's decision to maintain the position. Remitly's technology platform and customer acquisition capabilities create sustainable competitive advantages in the evolving financial services landscape.

Pitch Summary:
Trimble, Inc. is a leading industrial technology company that provides hardware, software, and services primarily to the construction, geospatial, transportation, and agricultural industries. Over the last several years, Trimble has been transitioning toward a subscription-based, recurring revenue model. The stock fell in the quarter when its 10K filing was delayed due to an audit that called for additional documentation of internal controls. We don't view the issue as material and the delay detracted from what otherwise was a very good quarter for its business and maintained our position in the company during the period.

BSD Analysis:
The manager demonstrates conviction in Trimble's long-term transformation story despite temporary administrative setbacks that pressured the stock price. The investment thesis centers on Trimble's successful transition from a hardware-centric model to a subscription-based recurring revenue business across construction, geospatial, transportation, and agricultural markets. This business model transformation enhances revenue predictability, customer lifetime value, and margin expansion potential. The manager's dismissal of the 10K filing delay as immaterial, while noting strong underlying quarterly performance, suggests confidence in the fundamental business trajectory. Trimble's leadership position in industrial technology solutions across multiple end markets provides diversification and growth opportunities. The recurring revenue transition creates more stable cash flows and higher valuation multiples typical of software businesses. The manager's decision to maintain the position during temporary weakness demonstrates conviction in the long-term value creation opportunity.

Pitch Summary:
Alight, Inc. is a leading cloud-based human capital technology provider of enterprise-level software that helps businesses and their employees manage critical human resources functions. Through its investments in software and automation, Alight has built a distinct advantage that allows its customers to deliver HR services at a much lower cost while providing a better experience for employees. We slightly trimmed the position early in the quarter when the stock appreciated on the announced sale of a non-strategic business unit and news that an activist investor had initiated a position. Later in the period, the stock declined when Alight announced weaker-than-expected results. We believe the softer quarter will prove to be an isolated event.

BSD Analysis:
The manager maintains a bullish stance on Alight despite recent quarterly weakness, viewing the company as a leader in cloud-based human capital technology with sustainable competitive advantages. The investment thesis is built on Alight's ability to deliver HR services at significantly lower costs while improving employee experience through software automation investments. This value proposition creates strong customer retention and pricing power in the enterprise HR market. The presence of activist investors and strategic asset sales suggest potential value realization catalysts ahead. The manager's conviction that the weak quarter represents an isolated event rather than fundamental deterioration demonstrates confidence in the underlying business model. Alight's cloud-based platform and automation capabilities position it well to capture market share in the growing HR technology outsourcing market. The combination of cost efficiency, superior user experience, and enterprise-grade solutions creates a compelling competitive moat.

Pitch Summary:
Agios Pharmaceuticals, Inc. is a leader in cellular metabolism and pyruvate kinase activation pioneering therapies for rare diseases. The stock appreciated in the quarter after it announced positive Phase 3 testing results of mitapivat, a therapy for adults with non-transfusion dependent thalassemia, an anemia blood disorder. With these results, we expect an FDA filing for the drug in the back half of this year for approval. The company also sold its 15% royalty on a cancer drug, which provided a boost to its cash position that could be used to further develop and market mitapivat. We trimmed our position in the company based on our valuation discipline as the share price appreciated.

BSD Analysis:
The manager's bull case for Agios centers on the company's leadership position in cellular metabolism and the significant clinical milestone achieved with mitapivat's positive Phase 3 results. The successful trial for non-transfusion dependent thalassemia positions the company for FDA filing and potential approval in the second half of the year, representing a major value catalyst. The strategic sale of cancer drug royalties strengthens the balance sheet and provides capital for mitapivat development and commercialization efforts. Agios' specialized focus on rare diseases through cellular metabolism creates a differentiated competitive position with significant barriers to entry. The manager's disciplined approach to trimming the position on appreciation demonstrates prudent risk management while maintaining exposure to the regulatory approval catalyst. The rare disease market offers attractive pricing dynamics and limited competition, supporting strong commercial potential for mitapivat upon approval.

Pitch Summary:
Chewy, Inc. is an online provider of pet food, supplies, and medications. The company's stock soared during COVID while customers accelerated online purchases and added pets to their families. Following a post-COVID correction, we re-established a position during the quarter at what we believe to be an attractive price. With nearly 80% of revenues recurring—a rarity for an online business—we believe Chewy is well-positioned to activate and grow its customer base. In addition, we can see its pharmacy business starting to improve net sales and margins per active customer and have high confidence in its new CFO. Both, in our view, could add significant value. The stock gained during the period as higher net sales per active customer increased almost 10%.

BSD Analysis:
The manager demonstrates opportunistic value investing by re-establishing a position in Chewy following the post-COVID correction at attractive valuations. The investment thesis is anchored on Chewy's exceptional recurring revenue profile, with nearly 80% recurring revenues being rare for online retail businesses. This provides predictable cash flows and strong customer retention metrics. The emerging pharmacy business represents a significant margin expansion opportunity while the new CFO brings additional operational expertise. The 10% increase in net sales per active customer validates the company's ability to monetize its customer base more effectively. Chewy's dominant position in the growing pet care market, combined with its subscription-like revenue model, creates a compelling long-term growth opportunity. The manager's timing appears astute, capitalizing on temporary market dislocation to establish a position in a high-quality recurring revenue business.

Pitch Summary:
Transmedics Group, Inc. is a medical technology company with a differentiated capability to facilitate organ transplants. Their Organ Care System (OCS) allows doctors to efficiently and successfully harvest and transplant more organs than traditional services, presenting a win-win for patients and surgeons alike. We believe the company's revolutionary technology and proprietary logistics network will continue to take market share while also expanding the addressable market. The company reported increased adoption and buildout of its OCS platform, strong top-line growth in the quarter, and profitability metrics which are ahead of plan. During the quarter, we trimmed our position on valuation discipline as the share price appreciated.

BSD Analysis:
The manager presents a compelling bull case for TransMedics based on the company's revolutionary Organ Care System technology that enables more efficient organ transplants. The investment thesis centers on market share gains and addressable market expansion through superior technology and proprietary logistics capabilities. Strong quarterly performance metrics including increased platform adoption, robust revenue growth, and ahead-of-plan profitability demonstrate solid execution. The manager's decision to trim the position on valuation discipline shows prudent risk management while maintaining conviction in the long-term opportunity. The organ transplant market represents a significant addressable opportunity with clear patient and surgeon benefits driving adoption. TransMedics appears well-positioned to capitalize on this growing market through its differentiated technology platform. The combination of strong fundamentals and expanding market opportunity supports the bullish investment stance.

Pitch Summary:
Amazon.com, Inc. is a global technology company that operates e-commerce, cloud computing, digital advertising, and other businesses. We own Amazon because we believe it is well-positioned to benefit from several strong secular trends, including the shift to online shopping, the growth of cloud computing, and the increasing importance of digital advertising. The company exceeded expectations in the first quarter, with cloud-computing revenue growth accelerating, driven by easing cost optimization pressures and the ramp of generative AI workloads. The North American retail segment drove record operating margins, highlighting the success of Amazon's efforts to improve efficiency and lower its cost to serve. International retail also showed promise, as emerging markets steadily progressed towards profitability. Given the strength across these key segments, we continue to hold the position in the company.

BSD Analysis:
The manager presents a comprehensive bull case for Amazon based on the company's exposure to multiple powerful secular growth trends including e-commerce adoption, cloud computing expansion, and digital advertising growth. The investment thesis emphasizes Amazon's diversified business model and market-leading positions across key segments. Strong first-quarter results validate the manager's confidence, with AWS cloud revenue growth accelerating as enterprise cost optimization pressures ease and generative AI workloads drive incremental demand. The North American retail segment achieved record operating margins, demonstrating the success of multi-year efficiency initiatives and cost structure improvements. International retail operations show encouraging progress toward profitability, particularly in emerging markets, expanding Amazon's global earnings potential. The convergence of operational excellence across all major business segments reinforces the manager's conviction in holding the position. Amazon's ability to monetize AI trends through AWS while maintaining retail market share leadership positions the company to benefit from multiple growth vectors simultaneously.

Pitch Summary:
Rivian Automotive, Inc. is a US-based electric vehicle manufacturer focused on the design, development, and production of electric adventure vehicles, pickup trucks, and commercial delivery vans. We own Rivian because we believe the company is a future leader in the growing electric vehicle market with a strong brand, compelling products, and a vertically integrated business model. During the quarter, Rivian's stock price was driven by its progress on cost reduction initiatives and management's stated confidence in achieving positive gross margins by the end of 2024. The recent announcement of a joint venture with Volkswagen, involving up to $5 billion in investment, also significantly boosted Rivian's financing outlook and validated its technology. We trimmed our position in Rivian given the strong performance in the quarter.

BSD Analysis:
The manager maintains a bullish outlook on Rivian Automotive, positioning the company as a future leader in the rapidly expanding electric vehicle market. The investment thesis emphasizes Rivian's differentiated approach through adventure-focused vehicles, strong brand identity, and vertically integrated manufacturing model. Key operational progress includes meaningful advancement on cost reduction initiatives and management's confidence in achieving positive gross margins by year-end 2024, representing a critical profitability milestone. The transformative Volkswagen joint venture, worth up to $5 billion, provides substantial validation of Rivian's technology platform while significantly strengthening the company's financial position and funding runway. This partnership reduces execution risk and provides access to Volkswagen's global manufacturing expertise and scale. The manager's decision to trim the position following strong quarterly performance demonstrates disciplined profit-taking while maintaining conviction in the long-term electric vehicle adoption trend and Rivian's competitive positioning within the adventure vehicle segment.

Pitch Summary:
Vistra Corp. is an integrated retail electricity and power generation company with operations across 20 U.S. states and Washington D.C. We identified Vistra as a likely beneficiary of the projected growth of power-hungry data centers, spurred by the rise of generative AI, increasing electricity demand, and higher power prices. The stock performed well after the company delivered stronger than expected earnings. Management also provided forward guidance that exceeded investors' expectations and reaffirmed shareholder-friendly plans for sizable share repurchases through 2025. We trimmed our position in the quarter following the strong performance and continue to see strong long-term prospects for the company.

BSD Analysis:
The manager presents a compelling bull case for Vistra Corp. centered on the company's positioning to benefit from the artificial intelligence-driven surge in data center electricity demand. The investment thesis capitalizes on the intersection of generative AI growth, increasing power consumption, and favorable pricing dynamics in electricity markets. Vistra's integrated model across retail and generation provides exposure to both volume growth and margin expansion opportunities. The company's strong quarterly performance, with earnings exceeding expectations, validates the manager's thesis about demand trends. Management's guidance raise and commitment to substantial share repurchases through 2025 demonstrates confidence in cash flow generation and shareholder-friendly capital allocation. The decision to trim the position following strong performance suggests disciplined portfolio management while maintaining conviction in long-term prospects. The AI-driven electricity demand theme positions Vistra as a beneficiary of a multi-year secular growth trend.

Pitch Summary:
U.S. Bancorp provides banking, payments, investment, trust, and mortgage services to consumers, businesses, and institutions. We own the company because of its historically strong profitability and consistent dividend payouts. The stock underperformed in the quarter due to a downward revision in net interest income guidance, driven by the ongoing shift from non-interest-bearing deposits to higher-cost interest-bearing accounts. To help mitigate the lower net interest income, management is focused on expense control initiatives. We are holding our position in U.S. Bancorp as we monitor the trajectory of net interest income and the success of these expense reductions.

BSD Analysis:
The manager maintains a bullish stance on U.S. Bancorp based on the bank's historically strong profitability metrics and consistent dividend distribution track record. The investment thesis appears grounded in the company's operational excellence and shareholder-friendly capital allocation policies. However, the bank faces near-term margin pressure from deposit mix shift, as customers migrate from non-interest-bearing accounts to higher-yielding alternatives in the current rate environment. This dynamic has forced management to revise net interest income guidance downward, creating headwinds for profitability. Management's response includes implementing expense control initiatives to partially offset the margin compression. The manager's decision to hold the position demonstrates confidence in management's ability to navigate the challenging operating environment through cost discipline. The strategy suggests patience with the cyclical nature of banking while maintaining conviction in the company's fundamental quality and long-term earnings power.

Pitch Summary:
The Walt Disney Company operates a diversified entertainment business with theme parks, media networks, and streaming services. We own Disney because we believe its strong brand, valuable IP, and expanding streaming offerings will drive sustainable long-term growth. The company's stock, however, underperformed in the quarter due to concerns about a slowdown in growth at its theme park division. While park revenue still grew by 10% year-over-year, management's commentary suggested a moderation in post-pandemic demand and rising costs, leading to a disappointing outlook for park operating income in the second half of the year. This overshadowed the positive news that the company's streaming segment, driven by strong subscriber growth at Disney+, reached profitability ahead of schedule. We held our position and will continue to monitor the performance of the theme park division.

BSD Analysis:
The manager maintains a bullish view on Disney despite quarterly underperformance, citing the company's strong brand equity, valuable intellectual property portfolio, and expanding streaming capabilities as key long-term growth drivers. The investment thesis appears focused on Disney's ability to monetize its content across multiple platforms and distribution channels. Near-term concerns center on the theme parks division, where management indicated a moderation in post-pandemic demand recovery and rising operational costs, leading to disappointing guidance for park operating income. However, the manager highlights a significant positive development with Disney's streaming segment achieving profitability ahead of schedule, driven by strong Disney+ subscriber growth. This milestone validates the company's streaming strategy and demonstrates progress in the competitive direct-to-consumer market. The decision to hold the position suggests confidence that streaming profitability can offset theme park headwinds over time.

Pitch Summary:
Liberty Sirius XM Group is a tracking stock that mirrors Liberty Media's ownership of Sirius XM Holdings, a leading provider of satellite radio and audio entertainment in North America. We own the stock because we believe Sirius XM possesses a durable business model with a stable subscriber base and a robust free cash flow profile. Furthermore, the stock has historically traded at a significant discount to its net asset value, providing an opportunity to acquire a substantial stake in Sirius XM at a lower price. The stock underperformed in the quarter as investor sentiment was dampened by concerns over slowing subscriber growth and competition from streaming services. We continue to have conviction in the company's competitive position and long-term value and held our position in the company.

BSD Analysis:
The manager maintains a bullish stance on Liberty Sirius XM Group despite recent underperformance, viewing it as an attractive way to gain exposure to Sirius XM Holdings at a discount to net asset value. The investment thesis centers on Sirius XM's durable business model characterized by a stable subscriber base and robust free cash flow generation. The manager acknowledges near-term headwinds including slowing subscriber growth and increased competition from streaming services, which pressured the stock during the quarter. However, they express continued conviction in the company's competitive positioning and long-term value proposition. The tracking stock structure provides an opportunity to acquire exposure to Sirius XM at what the manager believes is a meaningful discount. The decision to hold the position despite quarterly underperformance demonstrates confidence in the fundamental thesis and suggests the manager views current weakness as temporary rather than structural.

Pitch Summary:
PlayAGS, Inc. is a designer and supplier of slot machines and other gaming hardware for the gaming industry. Among the many things we like about this company are its seasoned management team, extensive gaming hardware design experience, and the recurring revenue generated through the gaming devices it sells to customers. The stock jumped on news that it would be acquired by private equity at approximately 40% above the prior 90-day average share price. We trimmed our position in PlayAGS during the quarter and will trade opportunistically as the transaction date comes into focus.

BSD Analysis:
The manager highlights PlayAGS's attractive business model characteristics including experienced management, proven gaming hardware design capabilities, and recurring revenue streams from device sales. The investment thesis was built on the company's competitive position in gaming equipment manufacturing with predictable cash flows. The private equity acquisition at a 40% premium validates the quality of the business model and management execution. The manager's neutral stance reflects the M&A situation rather than operational concerns, with tactical position management around deal timing. The premium paid suggests private equity recognition of the recurring revenue model's value and potential for operational improvements. The gaming industry's equipment replacement cycle provides steady demand for innovative slot machine designs.

Pitch Summary:
Silk Road Medical, Inc. is a medical technology and device company that has pioneered a minimally invasive approach to the treatment of carotid artery disease. The firm's transcarotid artery revascularization (TCAR) procedure has only a low double-digit share of a ~$1.2 billion market currently dominated by carotid endarterectomy (CEA), a more invasive procedure that carries a higher risk of procedural complications and death. The stock rose when it announced that it would be acquired by Boston Scientific at a 38% premium over its prior 60-day average share price. We trimmed the position on the news and will opportunistically liquidate as the transaction closing date approaches.

BSD Analysis:
The manager outlines Silk Road Medical's compelling market opportunity in carotid artery disease treatment through its minimally invasive TCAR procedure. The investment thesis was based on market share gains in a $1.2 billion market dominated by more invasive CEA procedures with higher complication rates. The low double-digit market penetration suggested significant runway for growth given the superior clinical outcomes. However, the Boston Scientific acquisition at a 38% premium validates the strategic value and technology differentiation. The manager's neutral stance reflects the M&A situation rather than fundamental concerns, with tactical position management around deal closure timing. The acquisition premium demonstrates the value of innovative medical device technologies that improve patient outcomes in large addressable markets.

Pitch Summary:
Transmedics Group, Inc. is a medical technology company with a differentiated capability to facilitate organ transplants. Their Organ Care System (OCS) allows doctors to efficiently and successfully harvest and transplant more organs than traditional services, presenting a win-win for patients and surgeons alike. We believe the company's revolutionary technology and proprietary logistics network will continue to take market share while also expanding the addressable market. The company reported increased adoption and buildout of its OCS platform, strong top-line growth in the quarter, and profitability metrics which are ahead of plan. During the quarter, we trimmed our position on valuation discipline as the share price appreciated.

BSD Analysis:
The manager presents a compelling bull case for TransMedics based on its revolutionary Organ Care System technology that improves organ transplant success rates. The investment thesis highlights both market share gains in existing transplant procedures and market expansion through enabling previously unusable organs. The proprietary logistics network creates a sustainable competitive moat in this specialized healthcare niche. Strong quarterly results showing increased platform adoption, robust revenue growth, and ahead-of-plan profitability metrics validate the commercial execution. The manager's disciplined approach to trimming on valuation appreciation demonstrates risk management while maintaining conviction in the long-term opportunity. The "win-win" value proposition for patients and surgeons supports sustainable adoption and pricing power in this critical healthcare application.